UroGen Pharma Ltd. (URGN)

US — Healthcare Sector
Peers: FENC  XOMA  KZR  TRDA  YMAB  ANAB  RYTM  WVE  SRRK 

Automate Your Wheel Strategy on URGN

With Tiblio's Option Bot, you can configure your own wheel strategy including URGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol URGN
  • Rev/Share 1.974
  • Book/Share -1.9559
  • PB -10.1128
  • Debt/Equity -1.3485
  • CurrentRatio 4.1404
  • ROIC -0.7763

 

  • MktCap 915103898.0
  • FreeCF/Share -2.5875
  • PFCF -7.4081
  • PE -6.0935
  • Debt/Assets 0.6033
  • DivYield 0
  • ROE 5.0346

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation URGN Piper Sandler -- Overweight -- $36 Aug. 19, 2025
Upgrade URGN H.C. Wainwright Neutral Buy -- $50 June 16, 2025
Downgrade URGN H.C. Wainwright Buy Neutral -- -- May 22, 2025
Initiation URGN Scotiabank -- Sector Outperform -- $23 April 16, 2025
Resumed URGN Ladenburg Thalmann -- Buy -- $31 Feb. 19, 2025
Initiation URGN Guggenheim -- Buy -- $40 Aug. 22, 2024

News

UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102
URGN
Published: February 14, 2025 by: Business Wire
Sentiment: Neutral

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from the subgroup analyses of the pivotal ENVISION study evaluating the impact of tumor burden and focality on the response to UGN-102, an investigational drug in development for treatment of LG-IR-NMIBC. Analyses of pre-specified subgroups showed comparable CR rates and DOR pa.

Read More
image for news UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102

About UroGen Pharma Ltd. (URGN)

  • IPO Date 2017-05-04
  • Website https://www.urogen.com
  • Industry Biotechnology
  • CEO Elizabeth A. Barrett
  • Employees 234
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.